Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 16;9(1):102684.
doi: 10.1016/j.rpth.2025.102684. eCollection 2025 Jan.

Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review

Umaima Abbas  1 , Robin MacKenzie  1 , Ushra Khan  1 , Rija Fatima  2 , Tzu-Fei Wang  3 , Rong Luo  4 , Caroline Hamm  1   5   6 , Andrea Cervi  1   5   6
Affiliations

Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review

Umaima Abbas et al. Res Pract Thromb Haemost. .

Abstract

Background: Patients with cancer-associated thrombosis (CAT) are at an increased risk of recurrent thrombosis and bleeding, especially if there is treatment- or disease-related thrombocytopenia. While direct oral anticoagulants (DOACs) are used in the management of CAT, low molecular weight heparin (LMWH) continues to be recommended for CAT with thrombocytopenia.

Objectives: This study aimed to identify the rates of recurrent venous thromboembolism (VTE) and bleeding in patients with CAT and thrombocytopenia treated with DOACs compared with LMWH.

Methods: A retrospective review of patients with CAT and thrombocytopenia (platelet count <100,000/μL) was conducted. Primary outcomes included rates of recurrent VTE and major bleeding over 90 days.

Results: Forty-two patients met the inclusion criteria; 20 (47.6%) had a solid organ malignancy while 22 (52.4%) had a hematologic malignancy. Within the first 7 days of VTE, 3 (7.1%) patients had a platelet count <25,000/μL, 9 (21.4%) had 25,000 to 50,000/μL, and 19 (45.2%) had 50,000 to 100,000/μL. Sixteen patients (38.1%) received a DOAC for initial treatment, while 19 (45.2%) received LMWH. Among patients treated with DOACs, there were no recurrent VTEs, 2 clinically relevant nonmajor bleeding events (12.5%) within the first 2 weeks, and 1 minor bleed (6.3%) in the second month, while those treated with LMWH had 1 recurrent VTE (5.3%) in the second month and 2 clinically relevant nonmajor bleeding events (10.5%) within the first 2 months.

Conclusion: Rates of thrombosis and major bleeding were similar among thrombocytopenic patients with CAT treated with DOACs and LMWH, although differences in baseline patient characteristics can be confounders. Further prospective research on the optimal anticoagulant management of CAT with thrombocytopenia is needed.

Keywords: direct oral anticoagulant; hemorrhage; neoplasms; thrombocytopenia; venous thromboembolism.

PubMed Disclaimer

References

    1. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–634. doi: 10.1111/j.1538-7836.2007.02374.x. - DOI - PubMed
    1. Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–1723. doi: 10.1182/blood-2013-04-460121. - DOI - PubMed
    1. Blom J.W., Doggen C.J.M., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–722. doi: 10.1001/jama.293.6.715. - DOI - PubMed
    1. Mulder F.I., Horváth-Puhó E., van Es N., van Laarhoven H.W.M., Pedersen L., Moik F., et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959–1969. doi: 10.1182/blood.2020007338. - DOI - PubMed
    1. Monreal M., Falgá C., Valdés M., Suárez C., Gabriel F., Tolosa C., et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006;4:1950–1956. doi: 10.1111/j.1538-7836.2006.02082.x. - DOI - PubMed

LinkOut - more resources